FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283212560> ?p ?o ?g. }

• W4283212560 endingPage "86" @default.
• W4283212560 startingPage "71" @default.
• W4283212560 abstract "Previous studies had limited power to assess the associations of circulating insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs) with clinically relevant prostate cancer as a primary endpoint, and the association of genetically predicted IGF-I with aggressive prostate cancer is not known. We aimed to investigate the associations of IGF-I, IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 concentrations with overall, aggressive and early-onset prostate cancer.Prospective analysis of biomarkers using the Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group dataset (up to 20 studies, 17 009 prostate cancer cases, including 2332 aggressive cases). Odds ratios (OR) and 95% confidence intervals (CI) for prostate cancer were estimated using conditional logistic regression. For IGF-I, two-sample Mendelian randomization (MR) analysis was undertaken using instruments identified using UK Biobank (158 444 men) and outcome data from PRACTICAL (up to 85 554 cases, including 15 167 aggressive cases). Additionally, we used colocalization to rule out confounding by linkage disequilibrium.In observational analyses, IGF-I was positively associated with risks of overall (OR per 1 SD = 1.09: 95% CI 1.07, 1.11), aggressive (1.09: 1.03, 1.16) and possibly early-onset disease (1.11: 1.00, 1.24); associations were similar in MR analyses (OR per 1 SD = 1.07: 1.00, 1.15; 1.10: 1.01, 1.20; and 1.13; 0.98, 1.30, respectively). Colocalization also indicated a shared signal for IGF-I and prostate cancer (PP4: 99%). Men with higher IGF-II (1.06: 1.02, 1.11) and IGFBP-3 (1.08: 1.04, 1.11) had higher risks of overall prostate cancer, whereas higher IGFBP-1 was associated with a lower risk (0.95: 0.91, 0.99); these associations were attenuated following adjustment for IGF-I.These findings support the role of IGF-I in the development of prostate cancer, including for aggressive disease." @default.
• W4283212560 created "2022-06-22" @default.
• W4283212560 creator A5006860546 @default.
• W4283212560 creator A5007768066 @default.
• W4283212560 creator A5008073132 @default.
• W4283212560 creator A5009120205 @default.
• W4283212560 creator A5010401322 @default.
• W4283212560 creator A5011703930 @default.
• W4283212560 creator A5011970350 @default.
• W4283212560 creator A5014422690 @default.
• W4283212560 creator A5014800121 @default.
• W4283212560 creator A5015603316 @default.
• W4283212560 creator A5015994795 @default.
• W4283212560 creator A5016405051 @default.
• W4283212560 creator A5017612596 @default.
• W4283212560 creator A5018863416 @default.
• W4283212560 creator A5019133187 @default.
• W4283212560 creator A5021492691 @default.
• W4283212560 creator A5023847764 @default.
• W4283212560 creator A5024041740 @default.
• W4283212560 creator A5026563364 @default.
• W4283212560 creator A5027838123 @default.
• W4283212560 creator A5027914604 @default.
• W4283212560 creator A5028698179 @default.
• W4283212560 creator A5030780402 @default.
• W4283212560 creator A5031594786 @default.
• W4283212560 creator A5032065827 @default.
• W4283212560 creator A5033124357 @default.
• W4283212560 creator A5035426339 @default.
• W4283212560 creator A5037920424 @default.
• W4283212560 creator A5038804932 @default.
• W4283212560 creator A5039379417 @default.
• W4283212560 creator A5039867286 @default.
• W4283212560 creator A5041918436 @default.
• W4283212560 creator A5042052338 @default.
• W4283212560 creator A5043960846 @default.
• W4283212560 creator A5044100781 @default.
• W4283212560 creator A5045581195 @default.
• W4283212560 creator A5046761446 @default.
• W4283212560 creator A5048196698 @default.
• W4283212560 creator A5049343588 @default.
• W4283212560 creator A5049753330 @default.
• W4283212560 creator A5051110113 @default.
• W4283212560 creator A5051995740 @default.
• W4283212560 creator A5053074659 @default.
• W4283212560 creator A5053483719 @default.
• W4283212560 creator A5053751519 @default.
• W4283212560 creator A5054621956 @default.
• W4283212560 creator A5056390607 @default.
• W4283212560 creator A5061697748 @default.
• W4283212560 creator A5063253944 @default.
• W4283212560 creator A5063459619 @default.
• W4283212560 creator A5064532620 @default.
• W4283212560 creator A5066410308 @default.
• W4283212560 creator A5067052917 @default.
• W4283212560 creator A5069226602 @default.
• W4283212560 creator A5069758850 @default.
• W4283212560 creator A5070118644 @default.
• W4283212560 creator A5072420085 @default.
• W4283212560 creator A5073405229 @default.
• W4283212560 creator A5074281181 @default.
• W4283212560 creator A5074402316 @default.
• W4283212560 creator A5074815814 @default.
• W4283212560 creator A5076018363 @default.
• W4283212560 creator A5078854117 @default.
• W4283212560 creator A5079162702 @default.
• W4283212560 creator A5079897358 @default.
• W4283212560 creator A5082146901 @default.
• W4283212560 creator A5083450375 @default.
• W4283212560 creator A5084578086 @default.
• W4283212560 creator A5085935506 @default.
• W4283212560 creator A5089976309 @default.
• W4283212560 creator A5091754121 @default.
• W4283212560 date "2022-06-21" @default.
• W4283212560 modified "2023-10-18" @default.
• W4283212560 title "Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer: a collaborative analysis of 20 prospective studies and Mendelian randomization analysis" @default.
• W4283212560 cites W2044826176 @default.
• W4283212560 cites W2066187800 @default.
• W4283212560 cites W2073836327 @default.
• W4283212560 cites W2117454704 @default.
• W4283212560 cites W2127768736 @default.
• W4283212560 cites W2134973552 @default.
• W4283212560 cites W2153117775 @default.
• W4283212560 cites W2169283889 @default.
• W4283212560 cites W2171694243 @default.
• W4283212560 cites W2274299408 @default.
• W4283212560 cites W2324862792 @default.
• W4283212560 cites W2407447102 @default.
• W4283212560 cites W2508534964 @default.
• W4283212560 cites W2528302205 @default.
• W4283212560 cites W2579779633 @default.
• W4283212560 cites W2612427157 @default.
• W4283212560 cites W2614566443 @default.
• W4283212560 cites W2770598799 @default.
• W4283212560 cites W2781138582 @default.
• W4283212560 cites W2792375985 @default.
• W4283212560 cites W2797389850 @default.
• W4283212560 cites W2803072880 @default.

• next